💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Troglitazone

CHEMBL408 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
441.5 g/mol
LogP
5.1
Phase
4

Troglitazone was the first thiazolidinedione (TZD) PPAR-gamma agonist approved for type 2 diabetes, acting by activating peroxisome proliferator-activated receptor gamma to improve insulin sensitivity in peripheral tissues including muscle, fat, and liver. It was withdrawn from the market due to severe idiosyncratic hepatotoxicity causing liver failure and death, despite its efficacy in reducing hyperglycemia and cardiovascular risk markers. It served as the prototype for subsequent TZDs (rosiglitazone, pioglitazone) with improved safety profiles.

الوزن الجزيئي

441,5000 g/mol

LogP

5,10

TPSA

110,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Cardiovascular Disease Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2

                

                

                
                

                    
InChI

                    
InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H27NO5S

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
الروابط القابلة للدوران

                        
5

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
31

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Troglitazone was the first thiazolidinedione (TZD) PPAR-gamma agonist approved for type 2 diabetes, acting by activating peroxisome proliferator-activated receptor gamma to improve insulin sensitivity in peripheral tissues including muscle, fat, and liver. It was withdrawn from the market due to severe idiosyncratic hepatotoxicity causing liver failure and death, despite its efficacy in reducing hyperglycemia and cardiovascular risk markers. It served as the prototype for subsequent TZDs (rosiglitazone, pioglitazone) with improved safety profiles.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Troglitazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL408.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5591.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.